je

DILS

: . ,

,

.
,
. ,
,
.

.
DILS 2013.
,

,
.

,
, .

, ,

.

,
.
,
, : .
, . , , .
, . , . , .
, . , . , .
, . , , .
... .

,
.
,
,

.
, , -
,
.
, ,

.

,
,

. ,

,
.

(. NICE SIGN ).

,
, .
, ;

.

: ,
.
( )

: .
(
)

( ):

/

I:

II:
IIa: /

ee IIb:
:.

III:

IV: ,

.
, ,
, ,
,

. .
, , ,

.
, ,
,
,

.
, ,
,

.
,
,

.
, , -

, , ,

, ,
,

, ,

6
. .
,
, ,

, ,
,

.
,

.
,

.
,
,

/
1. ,
2. ()
3.

4. ,

5. ,
6. :

7.

A () .
, , ,
. ,
, ;
,
.
610% 65.
. (6070%) ,
: (),
() . (2011. ),
17,7% 65 ,
.

,
.
. (2,55%).

8

,

.

1. ,

1.1. ()
() : )
(, ); )
,
,
.
, 1.
( = 1,90 95%CI1,552,33), ,
( 1,5995% CI1,351,86),
( 1,82 95%CI1,192,78)
( NICE Guideline, 2007).
1.

(95%CI)

: 1,61 (1,161,24)

: 1,39 (1,171,66)

: 1,60 (1,341,92)

:1,50 (1,161,94)

: 1,59 (1,152,20)

9
 .
( 65 69 1,2:1 ,
70 85 1,6:1 , 85 2:1 );

.

,
2,5 5% ( ),
.
,
. 1,
2 (PS-2) 13 ; 14,
1 (PS-1) 185 21,
33 .
, 1525% ,
;
. (APO) 19. ,
( P-4 1011
,
)( NICE Guideline, 2007). , GWS
(REM2,
Clusterin (CLU) , Phosphatidylinositol-binding clathrin assembly protein (PICALM) ,
Complement receptor 1 (CR1) , ATP-binding cassette sub-family A member 7 gene
(ABCA7), Membrane-spanning gene cluster (MS4A6A/MS4A4E), Ephrin receptor A1
(EPHA1), CD33, CD2AP) (Guerreiro NEJM 2013; (368)2; Neumann NEJM 2013).

:

,
, , .
,
.

10
 ( ), ,
75 ,
(FriedlandNandi, 2013).

, ( 2).

2.
( Gorelick, 2011)



SHEP 16% ;

Syst-Eur 50% (076%) 23 7
; p=0,05
PROGRESS 12% (-8% 28%) 34% (3% 55%)
; p=0,2 ; p=0,03
1% (-24% 22%) ;p=0,9
SCOPE 7% ; p>0,20

HYVET 14% (-9% 23%) (164 )

; p=0,2 (84 )
PRoFESS ;
p=0,48
;

()
, ,
OR
1,2 (CI 95% = 1,051,4) ( 3) (FriedlandNandi, 2013).
. ,
2, ,
(yuex, 2012).

11
 ,
.
3.
a

Peila, 2002. 77 ; RR (95%CI)1,7 (1,02,8)

Yamada, 2003. 43 ; RR 4,4

Akomolafe, 2006- 70 ;
RR(95%CI) 2,98 (1,068,9)
Ott, 1999. 69 ; RR (95%CI) 1,9 (1,23,1)

Luchsinger, 2001. 76 ; RR(95%CI) 2,4 (1,83,2)

RR(95%CI) 2,0 (1,42,9)
Arvanitakis, 2005. 75 ; RR (95%CI)1,7 (1,12,5)

Xu, 2004. 81 ; RR (95%CI) 1,3 (0,81,9)

RR (95%CI)1,3 (0,92,1)
Luchsinher, 2005. 76 ; RR (95%CI) 2,4 (1,83,2)
RR (95%CI) 2,0 (1,42,9)
Curb, 1999. 53 ; RR (95%CI) 1,0 (0,52,0)

Hassing, 2002. 84 ; RR (95%CI) 0,8 (0,51,5)

MacKnight, 2002. 74 ; RR (95%CI) 1,2 (0,81,8)

RR (95%CI) 1,3 (0,82,0)

.

(
4).
, .

4.
( Duron Hannon, 2008)

12
a

Notkola, 1998. 4059 ;
RR (95%CI) 3,1 (1,28,5)
Kivipelto, 53 ;
2002. RR (95%CI) 2,8 (1,26,7)
Moroney, 75 LDL ;
1999. RR (95%CI) 3,1 (1,56,1)
Kalmijn, 2000. 52,7
;
RR (95%CI) 1,10 (0,951,26)
Tan, 2003. 76
;
RR (95%CI) 0,97 (0,901,05)
Reitz, 2004. 78 LDL
; RR (95%CI) 0,48 (0,260,86)
Mielke, 2005. 70
;
RR (95%CI) 1,3 (0,81,9)
RR (95%CI) 0,31 (0,110,85)

6073%
,
(Duron Hannon, 2008). ,

( 5).

5.
( Shepardson, 2011)
a

Felman, 2010.

13
Friedhoff, 2001.

Heart Protection Study Collaborative

Group, 2002.
Shepard (PROSPER), 2002.

Sparks, 2005.

(HR 1,39; 95%CI=1,031,87).
(HR
0,63; 95%CI= 0,440,91), (1,62; 95%CI=1,022,64).
(Barnes Yaffe, 2013).

13
:
7 - RR 2,01; 95%CI 1,163,50
RR 1,87;95%CI 1,093,20(Barnes Yaffe, 2013).
20 102.172
: 9 - R 2,03 (95%CI 1,732,38) 11
R 1,90 (95%CI 1,552,33). (BarnesYaffe, 2013).


, .

.
(,
.).(

.)

14
( 1,161,79).
.

P-4 .
1.2.
(
, ,
, , , ,
)
.
, (HR 0,39) ,
.
, , ,
, ( ), ,
, ,
,
, .

( : 1, 6, 12; , , )
,
.

, 11

.

( 20 30 ) (
NICE Guideline, 2007).

(Mayeux Stern, 2012).

15
 6. ( Mayeux Stern,2012)

( .
)




II

II


,

,
,
, 2, .

1.3.

, .


(Snitz ., 2009).
(Deosky

16
.,2009; Vellas ., 2012). ,
, , , .

1.4.
()
(8)
() 16
.

, ,
.
,
.

,
, .
,
.

10 20%
65 .
, 5
10% (12% ), 10 15%
, ,
12 %. 4550%
.

. ,
,
, ,
.
,
.

17
 () , , ,
(7).

7. ,





/ / /

2.

( ) (
)( Albert .,2011).

2.1.
1. , ,

;
2.
;
;

18
3.
(. ,
).
;
4.

.
.

.

2.2.

.
, 1 1,5

( ).
, .
2.2.1.
,

, ,
.
FreeandCuedSelectiveRemindingTest(FCSRT),
RyAuditoryVerbalLearningest(RAVLT),CaliforniaVerbalLearningTest(CVLT),
LogicalMemoryIandII, VisualReproductionSubtestWechslerMemoryScale/ Revised.
,
, , .
,
(.
, . 14, ,
,. ,
, , ) .
,

19
 .,

. je
.

2.3.
,
,
: ();
;
.
o ,
, .
-
( , 1, 2), .
,
4 A ,
. A 4
,
.

8. (
Albert ., 2011)

1.
(
);
2.
,
/
;
3. ;
4. ;

20
5.
:
6. , ,
;
7. , ;
8. , .

.

.

2.4.
(

),
.
: ) -
(- -,
- ); )
( ,
(),
- Single Photon Emission Computed Tomography (SPECT)
,
.

( 9)
1.
- ;
.
2.
) -
;

21
 ) -
.


.
.
3.
,
;
.
4.
, -
.
: )
, ;) DAT SCAN
:) G-, DWI MRI

(
6 )
);)
, ,
.

9. (
)
- (
) ( , ,
)
, ,
,

22


,
(
),



,
(
)

,
.
,
, .

23

,
.

,
,
.

2.5.

1.
.
.
.
2. , , ,
(
EFNS Guidelines, Hort, 2010).
3.
,
.
4.
1984.
81%
70%.
.
,
( McKhann, 2011):

1.
,

.

24
 2.
(,
, ).
3. , ,
.
4. ,
.
5. -
, 1, 2, .
6.
40
. 90
.
7. ,
, .

(
McKhann, 2011):
,
.

() :
1.
();

2. ;
3. ;
4. :(1)
; 2)
.

.

25
 4.
:
) ;
: , ,
, ;
) ,
; : ,
, ,
;
) ; :

,
, ;
) (, , ); :
, ,
;
) ;
: ,
, , ,
, , ,
.
,
.

o .

,
.
1. : :

1.1. :

. ,
;
. ;
26
. ,
:
. : ,
.

;
. :
: ,
;
:
, ,
() .
;
: ,
.
. :
) ,
;

;
) ;
) ;
) /
;
) ,
.


:


.

27

( , 1, 2),
. 4
,
.
:


, ,

.

:
a) ,

;
( );
b) ;
c)
.

-: 42
.
: ( );
,
,
.
.
,
. :
1)
;

28
 2) .

,

.

1)
,

.
2) ,
.

( 9).
,

.

:
1) ;
2)
, ,
, ,
;
3) ,
.
A
29
:
/
( ).

: TSH, fT4, 12,

, ;

,
. FDGPET SPECT
,
, 65.
.- .

, ,
,
, 65. ( ).

(), (-
), ,
, . :
, 14, , ),
( 10).

,
:

24/30,

27/30,

21 19

30

.

10.

:
?


?

?
/?

()
- ()
, .

,
, .

,
( , 1 2, ).
(4 )
, .
.

31

, ; ,
()
( EFNS Guidelines, Hort, 2010).

3.

!

.
75%
.

3.1.

, ,
. (
),
( EFNS
Guidelines, Hort, 2010).

(, , )

.
,
;

.
,
( 16 26).

32

- (
). ( ),
.
(<10).
Cochrane Review (2006) ,

. .
( )
,
; ,
.
.
5 .

10 ,
. , ,
, , .
,
.
2 1,5
1,5 .
612 , , a
.
4,6-
, 9,5-
. ,
. .

8 , ,
16 ,
.
24
.

33
 ,
:
1. ;
2.
;

45 ;
3. 4070% ;
4.

.

, , -
-- () .
5 , 5
20
. , , ,
.
.

, ;

.

, ,
, e
(
)( EFNS Guidelines, Hort, 2010).

34
 7 (, ,
, , )
1025% (1,13 ).
Alzheimer Society- 2004., 4.000
(,
),
.

( EFNS
Guidelines, Hort, 2010)

1. , ,

.
. 3 4.
2. :
.
;
. .

3. :
. (,
).

.
, ,
4. ,
, ,
,
,
.
5. ,
.

35
 -
6.000 ( 2.548
, 380 )

, , ,
.
:
1. ,
.
2. , ,
.
3.
.
. , ,

.
.
(),

.
)
, , ;
) ,

.
4. , -,

.

( EFNS Guidelines, Hort, 2010)

36
 : , , ,
( 12 ), , ,
, , , ,
,
.

(Snitz ., 2009).

(Deosky .,2009; Vellas ., 2012). ,
, ,
, . ,

: , , , ,
, , 12
.

4.

4.1. ()

()
8090% ,
, .
( , , ),
, , ,
, , , , .
, ,
, ( ) (
APAGuideline, 2007; BCMAGuideline, 2008).

,

37
 . ,
.

,
( BCMAGuideline, 2008).
,
, , ,
, ,
.
: , ,
, , ,
, , ,
, .

:
:
(, ,
);
:
, , ,
. ,
.

.

38
 , ,
.
.

.
e ,
,
. ,
, , ,
. ,
, .
,
.
, ,
. ,
,
( , , ,
) ( NICE Guideline, 2007).

, ,
,
.

(NICE
Guideline, 2007). , , ,
, , ,
, .

-
. ,
.

39

.

( ,
), ( ).
(, ,
) .
,
, ,
,
( BCMA Guidelin, 2008).
( ),
, ,
( PAGuideline, 2007).
,
, . ,
.
, .
, .
,
( NICE Guideline, 2007).
,
,
( BCMA, 2008).
4.2.

, ,
.
,
. -j

.
, , ,
,

40
 .
, ,
.
. ,
()
,

.
. :
, , , , , ,
( 11).
, , . ,
5HT2A/ ,
( 25 50
200 ).
.
, 12
.
11.
(/) (/)

10 1040
25 25200
10 1040
10 1040
5 520

150 300
7,5 1545
37,5 75225

4.3.

41
 ,
, .
.
50%
.
.


, ,
.

, ,
. .
, .
12.
12.
(/) (/)

5 10
3 12
4,6 9,5
8 24
( ) 150 300

2,55 20

, ,
,
. ,
, ,
, ,
, (. ,

42
 ).
(, , , ,
) ( 0,5 1 46
13 , 0,25 0,5 , 12 ),
.
0,5 2 .
,
,
( BCMA Guideline, 2008,
APAGuideline, 2007).

50% ,
, .
.
/
, ( 0,25 2 ),
( 2,510 ), ( 25 )
( 200 ).
.
( APAGuideline, 2007),
,

, .
, 13 , ,
, , .
,
.
/
: ) ()
( , , , ,
),
(, , , , , ) ) ,
(, ,
, , , ),

43
 (, , ).
, ,
,
. , ,
, ;
.
,
, , ,
( 13). ,
, ,
, ( 13).

(
, ), ,
. ,
. , ,
, .
.
.
,
.

,
(.
), ( 0,5 1 46 13
), ( 0,5 2 ).
50 100 ,
,
600 800 . ,
,
( APAGuidelines, 2007).
13.

44
 0,250,5 (12x) 0,25 37 1 2
2,55 (1x) 2,55 37 77,510
2550 (2x) 50 2 a 37 2200
25 25 37 510
0,250,5 (12x) 0,25 37 1 2

( , ),
.

4.4.
2550% ,
( ,
, ,
), ,
( .)
, .
, ,
, ,
.

, ,
,
( APAGuideline, 2007).
,
( ),
. (25100
), (510 ), (510 )
(0,51 ).
( APA
Guideline, 2007).
5.

45


.
, .

,
.
.
1.1.

.
1.2.
, .
1.3. , (
10) :
)
;
) ,
;
) ;
) : , ,,
;
) ,
,
;
) : , ,
, , , , ,
, o .
1.4. . ,
, ,
.
1.5., o
, ,
, , , , ,

46
.
.
1.6.
.

6. :

, a
, ,
.
,

,
, .

, ,
,
.

,
, , , ,
, .
,
, ,
,
, , e , e

. ( NICE Guideline, 2007)

,
. ,

(

47
 )
.
,
( ,
20 ).
,
,
( NICE
Guideline, 2007).

,
,
.
,


.

7.

,
, .
:


.
e

(.
).
,
/ .
.

48
1.


,
.
2.
,
.
3. ,
,
.
4.
.
5.
.

49


Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment
due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on
diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270-9.

APA Work Group on Alzheimer's Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider
LS, Tariot PN, Blass DM. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's
disease and other dementias. Second edition. Am J Psychiatry. 2007 Dec;164(12 Suppl):5-56.

Barnes De, Yaffe K. The projected impact of risk factor reduction on Alzheimers disease prevalence. Lancet Neurol
2011;10(9):819-828.

Cognitive Impairment in the Elderly Recognition, Diagnosis and Management. Guidelines and Protocols. British Columbia
Medical Association (BCMA), Revised 2008.

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, et al; Ginkgo Evaluation of Memory
(GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA
2008;300(19):2253-62

Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008;4(2):363-81.

Friedland RP, Nandi S. A modest proposal for a longitudinal study of dementia prevention (with apologies to Jonathan Swift,
1729). J Alz Disease 2013;33:313-315.

Gorelick PB, Scuteri A, Black SE, et al. Vascular Contribution to Cognitive Impairment and Dementia: A Statement for
Health Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42:2672-2713.

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, etal; Alzheimer Genetic Analysis Group. TREM2
variants in Alzheimer's disease.N Engl J Med 2013;368(2):117-27.

Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P; EFNS Scientist Panel on Dementia.
EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010;17(10):1236-48.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ,
Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH.The diagnosis of
dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association
workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement2011;7(3):263-9.

Mayeux R, Stern Y. Epidemiology of Alzhemier Disease. Cold Spring Harb Perspect Med 2012; doi:
10.1101/cshperspect.a006239.

National Collaborating Centre for Mental Health (UK). Dementia: A NICE-SCIE Guideline on Supporting People With
Dementia and Their Carers in Health and Social Care. Leicester (UK): British Psychological Society; 2007.

Neumann H, Daly MJ. Variant TREM2 as risk factor for Alzheimer's disease. N Engl J Med 2013;368(2):182-4. J
Alzheimers Dis 2013;33(2):313-5.

Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol and Statins in Alzheimers Disease: II Review of Human Trials and
Recommendations. Arch Neurol 2011;68(11):1385-1392.

SnitzBE, O'MearaES, CarlsonMC, ArnoldAM, IvesDG, RappSR, etal; GinkgoEvaluationofMemory (GEM)

StudyInvestigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA
2009;302(24):2663-70.

Vellas B, Coley N, Ousset PJ, Berrut G, Dartigues JF, Dubois B, et al; GuidAge Study Group. Long-term use of standardised
Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet
Neurol 2012;11(10):851-9.

50